



LUNCH SYMPOSIUM

You are invited!

ECR 2026

Vienna, Austria

Thursday, March 5th, 2026

13:00 – 14:00

Room E2 (Level 0)

Advancing diagnostic MRI: high relaxivity gadopiclenol (Vueway) and the potential of artificial intelligence (AiMIFY™) in routine practice

Moderator: Prof. Konstantin Nikolaou

Faculty

Prof. Konstantin Nikolaou
(Tübingen, Germany)

Prof. Andrea Rossi
(Genoa, Italy)

Prof. Daniela Bernardi
(Milan, Italy)

Prof. Josef Vymazal
(Prague, Czech Republic)

General description

Gadopiclenol (Vueway) is a highly stable, macrocyclic, gadolinium-based contrast agent (GBCA) with the highest r_1 relaxivity of all GBCAs that are currently available or in development. The benefits of high relaxivity are that it can be administered at a lower dose without loss of diagnostic efficacy and that less gadolinium enters the environment. Lower Gd doses may be particularly beneficial in young, pediatric patients and in patients that require long-term regular MRI screening or follow-up. This symposium includes presentations by Prof. Andrea Rossi on the overall safety and benefits of low dose, high relaxivity Vueway for pediatric imaging and Prof. Daniela Bernardi on the advantages of Vueway for imaging of the breast. Finally, even with the highest r_1 relaxivity available, some lesions may remain poorly visible at the approved GBCA dose. The symposium concludes with a presentation by Prof. Josef Vymazal on the improved lesion conspicuity provided by AI (AiMIFY™) when used in conjunction with Vueway at its approved dose.

Gadopiclenol Safety and efficacy in pediatric neuroimaging

Prof. Andrea Rossi

Enhanced breast imaging with low dose, high relaxivity gadopiclenol (Vueway): assessing the benefits across different patient groups

Prof. Daniela Bernardi

Boosting diagnostic confidence: Vueway meets AI (AiMIFY™) for improved lesion visualization

Prof. Josef Vymazal

This program will also be available
24 hrs after live streaming on

<https://connect.myesr.org/>

**UNLOCKING THE
INVISIBLE**

